313 related articles for article (PubMed ID: 19169287)
21. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
[TBL] [Abstract][Full Text] [Related]
22. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
Kim JE; Lee DH; Yoo C; Kim S; Kim SW; Lee JS; Park CJ; Huh J; Suh C
Leuk Res; 2011 Feb; 35(2):183-7. PubMed ID: 20684990
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
[TBL] [Abstract][Full Text] [Related]
24. High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study.
Andion M; Molina B; Gonzalez-Vicent M; Alonso L; Hernandez C; Lassaletta A; Lopez-Ibor B; Villa M; Diaz MA
J Pediatr Hematol Oncol; 2011 Apr; 33(3):e89-91. PubMed ID: 21358341
[TBL] [Abstract][Full Text] [Related]
25. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
[TBL] [Abstract][Full Text] [Related]
26. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
27. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW
Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588
[TBL] [Abstract][Full Text] [Related]
30. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
31. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.
Smith SD; Bolwell BJ; Rybicki LA; Brown S; Dean R; Kalaycio M; Sobecks R; Andresen S; Hsi ED; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2007 Aug; 40(3):239-43. PubMed ID: 17530000
[TBL] [Abstract][Full Text] [Related]
32. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide.
Dean RM; Pohlman B; Sweetenham JW; Sobecks RM; Kalaycio ME; Smith SD; Copelan EA; Andresen S; Rybicki LA; Curtis J; Bolwell BJ
Br J Haematol; 2010 Jan; 148(2):226-34. PubMed ID: 19821828
[TBL] [Abstract][Full Text] [Related]
33. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma.
Kiss TL; Panzarella T; Messner HA; Meharchand J; Reddy V; Schimmer AD; Lipton JH
Bone Marrow Transplant; 2003 Jan; 31(2):73-8. PubMed ID: 12621486
[TBL] [Abstract][Full Text] [Related]
34. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma.
Copelan EA; Penza SL; Pohlman B; Avalos BR; Goormastic M; Andresen SW; Kalaycio M; Bechtel TP; Scholl MD; Elder PJ; Ezzone SA; O'Donnell LC; Tighe MB; Risley GL; Young DC; Bolwell BJ
Bone Marrow Transplant; 2000 Jun; 25(12):1243-8. PubMed ID: 10871728
[TBL] [Abstract][Full Text] [Related]
35. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
36. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Chen CI; Roitman D; Tsang R; Stewart AK; Keating A; Crump M
Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
[TBL] [Abstract][Full Text] [Related]
37. Intravenous busulfan-cyclophosphamide as a preparative regimen before allogeneic hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia.
Tang W; Wang L; Zhao WL; Chen YB; Shen ZX; Hu J
Biol Blood Marrow Transplant; 2011 Oct; 17(10):1555-61. PubMed ID: 21549217
[TBL] [Abstract][Full Text] [Related]
38. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Rossi HA; Becker PS; Emmons RV; Westervelt P; Levy W; Liu Q; Clark Y; Ballen K
Bone Marrow Transplant; 2003 Mar; 31(6):441-6. PubMed ID: 12665838
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
40. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis.
Jantunen E; Itälä M; Juvonen E; Leppä S; Keskinen L; Vasala K; Remes K; Wiklund T; Elonen E; Nousiainen T
Bone Marrow Transplant; 2006 Feb; 37(4):367-72. PubMed ID: 16415893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]